niraparib (Zejula)
Jump to navigation
Jump to search
Indications
- maintenance treatment for recurrent epithelial cancers*
- ovarian cancer[2][3]
- fallopian tube cancer
- primary peritoneal cancer[1]
- triple-negative breast cancer (HER2-, ER-, PR-) in combination with pembrolizumab[3]
* for patients with complete or partial response to platinum-based chemotherapy[1]
Contraindications
Dosage
Adverse effects
- anemia, thrombocytopenia, neutropenia or leukopenia
- bone marrow suppression, myelodysplastic syndrome
- palpitations
- dry mouth, mucositis, dysgeusia
- nausea, constipation, vomiting, abdominal pain, abdominal distension, diarrhea, dyspepsia
- fatigue, decreased appetite
- urinary tract infection
- increased serum transaminases
- myalgia, arthralgia
- headache, dizziness
- insomnia, anxiety
- dyspnea, cough
- rash
- hypertension, including hypertensive crisis
Mechanism of action
- inhibits poly ADP-ribose polymerase
More general terms
Component of
References
- ↑ Jump up to: 1.0 1.1 1.2 FDA News Release. March 27, 2017 FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm548948.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Jump up to: 2.0 2.1 Mirza MR, Monk BJ, Herrstedt J et al Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27717299 Free Article
- ↑ Jump up to: 3.0 3.1 3.2 Fuerst ML with expert critique by Sumrall AL Advanced TNBC: 'Durable Activity' for Niraparib + Pembrolizumab. Also benefit for platinum-resistant/refractory ovarian cancer. MedPage Today. ASCO Reading Room 06.21.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/73611